摘要目的 观察康柏西普玻注射液治疗渗出型老年性黄斑变性(AMD)的临床疗效及安全性.方法选择临汾市中心医院2016年10月至2017年10月诊治的渗出型AMD患者300例(300只眼),采用随机数字表法分为两组,观察组(150例,150只眼)行玻璃体腔注射康柏西普注射液0.05 mL,每月1次,治疗3个月.对照组(150例,150只眼)采用保守治疗.患者随访12个月,对比两组最佳矫正视力(BCVA)、黄斑中心凹厚度(CMT)、生存质量量表评分、临床疗效、并发症发生情况.结果 治疗后9个月,观察组、对照组BCVA分别为(0.55 ±0.11)、(0.51 ±0.15),治疗后12个月观察组、对照组BCVA分别为(0.59 ±0.21)、(0.53 ±0.11),观察组均高于对照组(t＝2.634、3.010,均P＜0.05);治疗后1个月、2个月、3个月、6个月、9个月、12个月观察组CMT均低于对照组(t＝5.321、20.035、25.593、22.456、26.326、27.005,均P＜0.05).末次随访时,观察组远视力、调节能力、读和精细工作、日常生活能力评分分别为(55.27 ±8.24)分、(30.21 ±5.20)分、(20.15 ± 5.01)分、(47.02 ±12.34)分,均高于对照组的(50.21 ±6.35)分、(25.34 ±4.17)分、(16.24 ±3.27)分、(40.25 ±9.25)分,差异均有统计学意义(t＝6.352、5.324、6.392、8.251,均P＜0.05).观察组总有效率为88.00%(132／150),高于对照组的76.67%(115／150),差异有统计学意义(χ2 ＝6.623,P＜0.05).两组均无严重并发症发生.结论 康柏西普玻注射液可显著提高渗出型AMD患者视力,提高生存质量,安全可靠,治疗AMD效果优于传统保守治疗.

abstractsObjective To investigate the efficacy and safety of conbercept injection in the treatment of exudative age－related macular degeneration ( AMD).Methods From October 2016 to October 2017,300 patients (300 eyes) with exudative AMD in Linfen Central Hospital were divided into two groups according to the random number table method.The study group (150 cases and 150 eyes ) received intravitreal injection of 0.05 mL of conbercept once a month for 3 months.The control group(150 cases and 150 eyes) received conservative treatment. All patients were followed up for 12 months after treatment.The differences of BCVA ,CMT,QOL,clinical efficacy and complications between the two groups were compared.Results BCVA was significantly increased and CMT was significantly decreased in the two groups after treatment,and BCVA was higher in the study group at 9 months [(0.55 ± 0.11) vs.(0.51 ±0.15)],12 months [(0.59 ±0.21) vs.(0.53 ±0.11)] after treatment compared with the control group(t＝2.634,3.010,all P＜0.05),and CMT was lower in the study group at 1－12 months after treatment(t＝5.321, 20.035,25.593,22.456,26.326,27.005,all P＜0.05).At the last follow－up,the distant vision,regulating ability, reading and fine work scores in the study group were (55.27 ±8.24) points,(30.21 ±5.20) points,(20.15 ± 5.01)points,(47.02 ±12.34) points,respectively, which were better than those in the control group [( 50.21 ± 6.35)points,(25.34 ±4.17)points,(16.24 ±3.27)points,(40.25 ±9.25) points](t＝6.352,5.324,6.392,8.251, all P＜0.05).The total effective rate of the study group [88.00%(132／150)] was higher than that of the control group[76.67%(115／150)](χ2 ＝6.623,P＜0.05).There were no serious complications in the two groups.Conclusion Conbercept injection can significantly improve the eyesight of exudative AMD patients ,improve the quality of life,it is safe and reliable,and its treatment effect for AMD is better than traditional conservative treatment .